Client Overview
Center for Outcomes Research in Liver Diseases (COR-LD) (Client Since 2014) is a pioneering research organization operating under CLDQ LLC. The organization is dedicated to advancing outcomes research in liver diseases through:
- Large database and economic analysis.
- Systematic reviews and meta-analyses.
- Managing Global Registries to study diseases like NASH/MASH, viral hepatitis, and ALD across different regions of the world.
- Collecting clinical data, laboratory metrics, and patient-reported outcomes (PROs) via custom questionnaires.
As a global research hub, COR-LD requires an enterprise-grade, highly reliable infrastructure to manage its vast, internationally sourced datasets and deploy accessible patient survey applications.
Business Challenges
COR-LD faced significant data and infrastructure challenges inherent to global medical research:
- Massive Data Volumes: The organization maintains clinical datasets containing over 10,000 patients, which requires substantial processing power.
- Global Accessibility: They needed a highly accessible, web-based platform to deploy patient questionnaires, such as the NAFLD Stigma Survey, directly to patients’ smartphones and computers.
- Secure Collaboration: The research relies on global collaborators entering de-identified clinical data through a centralized, password-protected platform.
- High-Performance Analytics: Their work requires deep querying capabilities for complex systematic reviews and extensive economic modeling.
MaxAPEX Solution
To power their global research initiatives, MaxAPEX deployed the MaxAPEX Custom plan, engineered specifically for COR-LD’s large-scale data and application requirements.
Key Implementations
Custom APEX Architecture
Hosted robust Oracle APEX environments specifically designed for web-based data collection, allowing the seamless deployment of patient surveys.
High-Capacity Data Infrastructure
Provisioned a custom database environment capable of scaling alongside their rapidly growing Global Liver Registries.
Secure & Centralized Access
Configured a protected hosting environment that allows global researchers to securely authenticate and log de-identified patient data without friction.
Results & Impact
⚡ Performance Improvements
- Sustained query performance and stability for datasets containing tens of thousands of complex patient records.
- Smooth, zero-latency experiences for patients accessing APEX-based survey links on mobile devices.
🔒 Reliability
- A continuous, secure, and password-protected platform enabling uninterrupted annual data entry by global sites.
- Flawless uptime supporting over a decade of critical medical research operations since 2014.
🏗️ Operational Efficiency
- Centralized management of massive external data sources, including inputs from Medicare databases and the National Inpatient Sample.
- Streamlined the systematic review process for epidemiology data.
Why MaxAPEX Was the Right Fit
| COR-LD Requirement | MaxAPEX Custom Solution |
| Massive Clinical Registries | Custom storage allocations for 10,000+ patient records. |
| Web-Based Survey Distribution | High-performance Oracle APEX application hosting. |
| Global Collaborator Input | Secure, centralized, and highly available global infrastructure. |
| Long-Term Data Retention | Enterprise-grade reliability and scalable database architecture. |
Future Roadmap
With the MaxAPEX Custom plan backing their infrastructure, COR-LD is positioned to:
- Continue expanding the enrollment of their Global NASH/MASH and Liver Registries worldwide.
- Deploy an increasing number of interactive, web-based APEX surveys to gather critical patient-reported outcomes.
- Run even more complex economic models based on expanding epidemiological data.
Conclusion
Since 2014, COR-LD has leveraged the MaxAPEX Custom plan to power its mission-critical outcomes research. By providing a scalable, highly secure, and APEX-optimized infrastructure, MaxAPEX has enabled COR-LD to successfully manage global registries and gather vital patient data, ultimately supporting their goal of better understanding the worldwide burden of liver disease.
